Skip to main content
Veterinary Medicines

Danilon Equidos NF 1.5 g/sachet granules in sachet for horses and ponies

Authorised
  • Suxibuzone

Product identification

Medicine name:
Danilon Equidos NF 1.5 g/sachet granules in sachet for horses and ponies
Danilon Equidos NF 1,5 g/tasak granulátum tasakban lovak és pónik számára A.U.V.
Active substance:
  • Suxibuzone
Target species:
  • Horse (non food-producing)
Route of administration:
  • Oral use

Product details

Active substance and strength:
  • Suxibuzone
    1.59
    gram(s)
    /
    3.00
    gram(s)
Pharmaceutical form:
  • Granules in sachet
Withdrawal period by route of administration:
  • Oral use
    • Horse (non food-producing)
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QM01AA90
Authorisation status:
  • Valid
Authorised in:
  • Hungary
Package description:
  • (ID2): 1 Box with 60 Sachet (Orientated PolyAmide, Aluminium, PolyEthylene) with 3 gram(s) (180 gram(s))
  • (ID1): 1 Box with 18 Sachet (Orientated PolyAmide, Aluminium, PolyEthylene) with 3 gram(s) (54 gram(s))

Additional information

Entitlement type:
  • Marketing Authorisation
Marketing authorisation holder:
  • Ecuphar
Marketing authorisation date:
Manufacturing sites for batch release:
  • Recipharm Parets S.L.
Responsible authority:
  • Directorate Of Veterinary Medicinal Products
Authorisation number:
  • 4210/X/20 NÉBIH ÁTI
Date of authorisation status change:
Reference member state:
  • Germany
Procedure number:
  • DE/V/0326/001
Concerned member states:
  • Austria
  • Belgium
  • Czechia
  • Denmark
  • Estonia
  • Hungary
  • Latvia
  • Lithuania
  • Norway
  • Poland
  • Romania
  • Slovakia
  • Slovenia

Documents

Summary of Product Characteristics

This document does not exist in this language (English). You can find it in another language below.
Hungarian (PDF)
Published on: 25/02/2022

Combined File of all Documents

English (PDF)
Published on: 4/10/2023
Download
How useful was this page?:
No votes yet
"Please do not include any personal data, such as your name or contact details. If you do, you consent to the processing of that data in accordance with EMA’s Privacy Statement concerning requests for information or access to documents. If you would like a reply from EMA, please Send a question to EMA instead."